Drug Trial Radar · NCT06152172
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Aug 5, 2024
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- David PorterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kyverna Therapeutics
- First posted
- Nov 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive 1 dose of KYV-101 and will be followed for 2 years.
Conditions
- Idiopathic Inflammatory Myopathies
- Diffuse Cutaneous Systemic Sclerosis
- SLE Nephritis
- ANCA Associated Vasculitis
Interventions
KYV-101Drug
The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.
CyclophosphamideDrug
Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2
FludarabineDrug
Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of AEs in IIM.Time frame: 3 months after CAR infusion.
- Incidence and severity of AEs in IIM.Time frame: 6 months after CAR infusion.
- Incidence and severity of AEs in IIM.Time frame: 12 months after CAR infusion.
- Incidence and severity of AEs in IIM.Time frame: 24 months after CAR infusion.
- Incidence and severity of AEs in DCSSTime frame: 3 months after CAR infusion.
- Incidence and severity of AEs in DCSSTime frame: 6 months after CAR infusion.
- Incidence and severity of AEs in DCSSTime frame: 12 months after CAR infusion.
- Incidence and severity of AEs in DCSSTime frame: 24 months after CAR infusion.
- Incidence and severity of AEs in SLE NephritisTime frame: 3 months after CAR infusion.
- Incidence and severity of AEs in SLE NephritisTime frame: 6 months after CAR infusion.
- Incidence and severity of AEs in SLE NephritisTime frame: 12 months after CAR infusion.
- Incidence and severity of AEs in SLE NephritisTime frame: 24 months after CAR infusion.
- Incidence and severity of AEs in AAVTime frame: 3 months after CAR infusion.
- Incidence and severity of AEs in AAVTime frame: 6 months after CAR infusion.
- Incidence and severity of AEs in AAVTime frame: 12 months after CAR infusion.
- Incidence and severity of AEs in AAVTime frame: 24 months after CAR infusion.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital of the Universithy of Pennsylvania
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.